Table 1.
Cases of HBV reactivation in patients treated with ibrutinib
| Ref | Age, yr | Sex | Cancer | Chemoa | Anti-CD20 | Ibrutinib dose, mg/d | Months from initial ibrutinib dose to reactivation | Baseline | Post-ibrutinib | HBV-associated hepatitisc | HBV-associated liver failure | Rxd | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-HBs | Anti-HBc | HBs Ag | HBV DNA, log10 IU/mL | HBsAg | Anti-HBs | HBV DNA, log10 IU/mL | |||||||||||
| 3 | 79 | M | CLL | No | No | 420 | 13.5 | + | + | − | − | N/A | − | 6.27 | Yes | Yes | TDF |
| 4 | 80 | M | CLL | Yes | No | 280 | 5 | + | + | − | 2.62 | + | + | 7.36 | Yes | No | ETV |
| 5 | 57 | M | CLL | No | Yesb | N/A | 42 | + | + | − | − | − | − | 2.96 | No | No | No |
| 5 | 75 | M | CLL | No | Yesb | N/A | 31 | + | + | − | − | + | N/A | 8.23 | No | No | ETV |
| 6 | 59 | M | CLL | No | Yesb | N/A | 1.5 | − | + | − | − | N/A | − | 2.86 | No | No | ETV |
| Current case | 68 | M | MZL | No | Yesb | 560 | 6 | − | + | − | − | + | − | 5.83 | Yes | Yes | ETV |
Anti-HBc, hepatitis B core antibody; Anti-HBs, hepatitis B surface antibody; Chemo, chemotherapy; CLL, chronic lymphocytic leukemia; ETV, entecavir; F, female; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; M, male; MZL, marginal zone lymphoma; N/A, not available; Ref, reference; Rx, treatment; TDF, tenofovir disoproxil fumarate; +, positive; −, negative.
a
Received within 12 months of HBV reactivation.
b
Anti-CD20 (rituximab) therapy was completed at least 24 months HBV reactivation in all cases.
c
ALT with median of 103 and range of 70–987 lU/l. We reported the peak values of ALT and HBV DNA.
d
All patients recovered after treatment.